PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories

Reported: December 11, 2024 Initiated: November 14, 2024 #D-0100-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Details

Units Affected
23,490 bottles
Distribution
PA, OH, PR
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories. Recalled by Amerisource Health Services LLC. Units affected: 23,490 bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on December 11, 2024. Severity: Moderate. Recall number: D-0100-2025.